Aaron M Wieland, MD

Associate Professor

  • Section of Head and Neck Surgical Oncology
  • Division of Otolaryngology-Head & Neck Surgery

Office: (608) 265-8207

  • Clinical Appointments: (608) 263-6190

600 Highland Ave
BX7375 Clinical Science Center-K4
Madison, WI 53792-3284


  • MD, Harvard Medical School, Boston, MA
  • Residency in Otolaryngology - Head & Neck Surgery, Massachusetts Eye and Ear Infirmary, Boston, MA
  • Fellowship in Head and Neck Surgical Oncology and Microvascular Reconstruction, University of Wisconsin Hospital and Clinics, Madison, WI

Clinical Specialties

Dr. Wieland is certified by the American Board of Otolaryngology. He specializes in treatment of head and neck cancer, voice and swallowing disorders, trauma, reconstruction, and robotic surgery. He is chief of the otolaryngology service at the William S. Middleton Memorial Veterans Hospital.

Recent Publications

  • Reconstruction After Skin Cancer Resection of the Head and Neck.
    Zimmer DI, Wieland AM, Ku JA
    Otolaryngol Clin North Am 2023 Aug; 56(4): 779-790
    [PubMed ID: 37277301]

  • Functional Outcomes After Transoral Plus Lateral Pharyngotomy Approach for Advanced Oral and Oropharyngeal Tumors.
    Colevas SM, Merfeld EC, Pflum ZE, Gessert TG, Wieland AM, Glazer TA, Burr AR, Harari PM, Hartig GK
    OTO Open 2023; 7(1): e35
    [PubMed ID: 36998565]

  • Interstitial Brachytherapy for Lip Cancer: Technical Aspects to Individualize Treatment Approach and Optimize Outcomes.
    Merfeld EC, Witek ME, Francis DM, Burr AR, Wallace CR, Kuczmarska-Haas A, Lamichhane N, Kimple RJ, Glazer TA, Wieland AM, McCulloch TM, Hartig GK, Harari PM
    Pract Radiat Oncol 2023; 13(4): 340-345
    [PubMed ID: 36709044]

  • Patterns of failure for hypopharynx cancer patients treated with limited high-dose radiotherapy treatment volumes.
    Burr A, Harari P, Wieland A, Kimple R, Hartig G, Witek M
    Radiat Oncol J 2022 Dec; 40(4): 225-231
    [PubMed ID: 36456541]

  • Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer.
    Witek ME, Kimple RJ, Avey GD, Burr AR, Chandereng T, Yu M, Hu R, Wieland AM, Labby ZE, Bruce JY, Brower JV, Hartig GK, Harari PM
    Am J Clin Oncol 2022 May 01; 45(5): 202-207
    [PubMed ID: 35446279]

All Publications on PubMed